Conglobatin exhibits significant antitumor activity, particularly through its ability to inhibit the proliferation of cancer cells by interfering with microtubule dynamics. It binds to tubulin, preventing proper assembly and disassembly of microtubules, which disrupts mitosis and leads to cell cycle arrest. This mechanism makes it a candidate for development in cancer chemotherapy, especially for solid tumors. Additionally, conglobatin has shown antimicrobial properties against certain drug-resistant pathogens, suggesting potential use in treating resistant infections. Research is ongoing to explore its efficacy and safety in preclinical models.